Contributions
Abstract: PB1887
Type: Publication Only
Background
The average age of the patients at the time of diagnosis is 72 and the incidence of CLL increases with age. Comorbidities, which increase by age, including coronary artery disease, heart failure, diabetes mellitus, chronic obstructive pulmonary disease and cognitive geriatric syndromes influence the performance status of the elderly patients leading to negative impact on treatment continuation and survival .
Aims
We aimed to investigate the clinical characteristics, the rate of treatment demand, time to treatment and mortality rates differ between c CLL patients <65 years and ≥ 65 years, which is the cut-off age for the definition of elderly by World Health Organization
Methods
A hundred and thirty-seven patients who were diagnosed and followed with the diagnosis of CLL were included in this retrospective analysis. The patients were diagnosed according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and Rai staging system was used for disease-staging. Patients were divided into two groups based on the World Health Organization (WHO) definition of elderly, which starts at age 65. Clinical characteristics, treatment demand, time to treatment and mortality rates of the two groups were compared. In a subgroup analysis, patients receiving treatment were also analysed according to age.
Results
There were 63 (46 %) patients aged < 65 years and 74 (54 %) patients ≥ 65 years. Two groups were comparable in term gender, Rai stage, WBC, ALC, Hgb level, Plt count, presence of splenomegaly, lymphadenopathy, Del 13q14, Del 11q22, Del 17p and Trisomy 12, time to treatment and treatment demand (p>0.05). Even though the difference was statistically insignificant, 28.6% (18/63) of the patients < 65 required treatment, while this rate was 44.6% (33/74) for patients ≥ 65.
We also analysed the patients, who received treatment, according to the age groups When we divided patients who received treatment into two groups as <65 years and ≥ 65 years the two groups were similarly comparable in terms of gender, age, WBC, ALC, Hgb, plt, Rai stage, presence of splenomegaly, lymphadenopathy, Del 13q14, Del 11q22, Del 17p and Trisomy 12, and time to treatment (p>0,05)
Conclusion
We found no difference in CLL patients who are younger and older than 65 in terms of clinical characteristics, disease stage, time to treatment and treatment demand. Mortality rates were higher in older patients with the upshot of comorbid diseases. The major limitations of our study were the limited number of patients and conducting with retrospective chart review.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Chronic Lymphocytic Leukemia, prognosis, Treatment
Abstract: PB1887
Type: Publication Only
Background
The average age of the patients at the time of diagnosis is 72 and the incidence of CLL increases with age. Comorbidities, which increase by age, including coronary artery disease, heart failure, diabetes mellitus, chronic obstructive pulmonary disease and cognitive geriatric syndromes influence the performance status of the elderly patients leading to negative impact on treatment continuation and survival .
Aims
We aimed to investigate the clinical characteristics, the rate of treatment demand, time to treatment and mortality rates differ between c CLL patients <65 years and ≥ 65 years, which is the cut-off age for the definition of elderly by World Health Organization
Methods
A hundred and thirty-seven patients who were diagnosed and followed with the diagnosis of CLL were included in this retrospective analysis. The patients were diagnosed according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and Rai staging system was used for disease-staging. Patients were divided into two groups based on the World Health Organization (WHO) definition of elderly, which starts at age 65. Clinical characteristics, treatment demand, time to treatment and mortality rates of the two groups were compared. In a subgroup analysis, patients receiving treatment were also analysed according to age.
Results
There were 63 (46 %) patients aged < 65 years and 74 (54 %) patients ≥ 65 years. Two groups were comparable in term gender, Rai stage, WBC, ALC, Hgb level, Plt count, presence of splenomegaly, lymphadenopathy, Del 13q14, Del 11q22, Del 17p and Trisomy 12, time to treatment and treatment demand (p>0.05). Even though the difference was statistically insignificant, 28.6% (18/63) of the patients < 65 required treatment, while this rate was 44.6% (33/74) for patients ≥ 65.
We also analysed the patients, who received treatment, according to the age groups When we divided patients who received treatment into two groups as <65 years and ≥ 65 years the two groups were similarly comparable in terms of gender, age, WBC, ALC, Hgb, plt, Rai stage, presence of splenomegaly, lymphadenopathy, Del 13q14, Del 11q22, Del 17p and Trisomy 12, and time to treatment (p>0,05)
Conclusion
We found no difference in CLL patients who are younger and older than 65 in terms of clinical characteristics, disease stage, time to treatment and treatment demand. Mortality rates were higher in older patients with the upshot of comorbid diseases. The major limitations of our study were the limited number of patients and conducting with retrospective chart review.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Chronic Lymphocytic Leukemia, prognosis, Treatment